On November 18, CRISPR Therapeutics AG rose 5.28% in Regular Trading, trading at $42.01 per share, with turnover of $9.2124 million.
The identifiable catalyst was continued market digestion of recent clinical updates for CTX310 and zugo-cel, alongside an analyst reiteration of a Buy rating with an $80 price target, which together helped support the rebound.
Recent company disclosures showed Phase 1b data for CTX310 in severe hypertriglyceridemia, where a single-course treatment produced mean reductions of 65% in ANGPTL3 and 63% in triglycerides. Separately, early autoimmune data for zugo-cel showed an 83% clinical response rate at Month 3 in systemic sclerosis patients receiving standard lymphodepletion. These developments came after the company’s latest quarterly EPS of negative $1.15 missed consensus, while revenue of $12.669 million exceeded expectations, underscoring that the latest share move is being driven primarily by pipeline news and external rating support rather than earnings alone.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)